Mitochondria-Penetrating Peptides  by Horton, Kristin L. et al.
Chemistry & Biology
ArticleMitochondria-Penetrating Peptides
Kristin L. Horton,1,3 Kelly M. Stewart,1,3 Sonali B. Fonseca,2 Qian Guo,1 and Shana O. Kelley1,2,*
1Department of Biochemistry, Faculty of Medicine
2Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy
University of Toronto, Toronto, ON M5S 3M2, Canada
3These authors contributed equally to this work.
*Correspondence: shana.kelley@utoronto.ca
DOI 10.1016/j.chembiol.2008.03.015SUMMARY
Mitochondriaare important targets for cancer chemo-
therapy and other disease treatments. Gaining ac-
cess to this organelle can be difficult, as the inner
membrane is a barrier limiting diffusive transport. A
mitochondrial molecular carrier would be a boon to
the development of organelle-specific therapeutics.
Here, we report a significant advance in the devel-
opment of mitochondrial transporters—synthetic
cell-permeable peptides that are able to enter mito-
chondria. Efficient uptake of thesemitochondria-pen-
etrating peptides (MPPs) is observed in a variety of
cell types, and organellar specificity is attained with
sequences thatpossessspecificchemicalproperties.
The MPPs identified are cationic, but also lipophilic;
this combination of characteristics facilitates perme-
ation of the hydrophobic mitochondrial membrane.
TheexaminationofapanelofMPPs illustrates thatmi-
tochondrial localization can be rationally controlled
and finely tuned by altering lipophilicity and charge.
INTRODUCTION
The mitochondrion represents a candidate of significant interest
for organelle-specific delivery of exogenous molecules (Fantin
and Leder, 2006; Galluzzi et al., 2006; Murphy and Smith,
2000). The roles of mitochondria in energy production and pro-
grammed cell death make this organelle a prime target in the
treatment of several disease states (Galluzzi et al., 2006; Green
et al., 2004; Murphy and Smith, 2000). Furthermore, cancer ther-
apies have targeted mitochondria to induce cell death in tumors
where conventional apoptotic pathways are disabled (Galluzzi
et al., 2006). A significant challenge to mitochondrial drug deliv-
ery is the impervious structure of the hydrophobic inner mem-
brane. Theoretical and experimental studies have revealed the
importance of lipophilicity and positive charge in molecules
that accumulate in the mitochondria, but the relationship be-
tween chemical structure and mitochondrial entry remains ill
defined (Fernandez-Carneado et al., 2005; Horobin et al., 2007;
Maiti et al., 2007; Modica-Napolitano and Aprille, 2001; Rosania,
2003; Rosania et al., 2003; Zhao et al., 2004). A precise
understanding of the determinants for mitochondrial entry is
critical to the development of a general class of syntheticChemistry & Biologmitochondrial transporters and to the optimization of therapeu-
tics with targets within this organelle.
While little is known about engineering molecules to penetrate
themitochondrial membrane, a major breakthrough in the identi-
fication of compounds that can penetrate the plasmamembrane
was made when a series of short peptide sequences were iden-
tified that exhibited efficient cellular uptake (Derossi et al., 1994;
Frankel andPabo, 1988;Green andLoewenstein, 1988).One that
has received a great deal of attention is the Tat peptide, derived
from the HIV transactivator protein (Green and Loewenstein,
1988). The discovery of this peptide, along with others displaying
membrane-crossing activities, served as the cornerstone for
a new subfield focused on the use of cell-penetrating peptides
(CPPs) as molecular transporters (Gupta et al., 2005; Joliot and
Prochiantz, 2004; Snyder and Dowdy, 2004). Numerous applica-
tions of CPPs as molecular delivery vehicles have been demon-
strated, illustrating their utility in biology and medicine (Goun
et al., 2006;Gupta et al., 2005; Joliot andProchiantz, 2004; Lewin
et al., 2000; Snyder and Dowdy, 2004; Torchilin et al., 2001).
Although the precise mechanisms of entry are still under debate,
some highly cationic CPPs have been shown to respond tomem-
brane potential (Fischer et al., 2005; Futaki et al., 2007; Henriques
et al., 2005; Rothbard et al., 2004; Terrone et al., 2003). This begs
the question: given the potential-responsive character of many
mitochondrial localizers (Davis et al., 1985; Horobin et al., 2007;
Modica-Napolitano andAprille, 2001), couldCPPsbeengineered
with the proper chemical attributes for transport into mitochon-
dria? Peptide-based mitochondrial agents would have many
advantages over other mitochondriotropics, including biocom-
patibility and straightforward synthesis, that would facilitate
modification with therapeutic cargos. Indeed, the prior develop-
ment of peptide-based antioxidants that exhibited mitochondrial
localization provides an important precedent for the feasibility of
such an approach (Zhao et al., 2004).
Here, we report the first, to our knowledge, systematic devel-
opment of a class of synthetic peptides that exhibit efficient
cellular uptake and specific mitochondrial localization. Using
design principles that impart properties facilitating efficient cellu-
lar uptake and mitochondrial entry, sequences were engineered
to display levels of cellular uptake that rival the Tat peptide, but
with strong mitochondrial localization, a property unattainable
with this CPP. Moreover, the exact physiochemical properties
leading to the organellar specificity of these mitochondria-pene-
trating peptides (MPPs) were identified, providing an important
conceptual framework for understanding how mitochondrial
localization can be achieved with synthetic compounds.y 15, 375–382, April 2008 ª2008 Elsevier Ltd All rights reserved 375
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Design and Preparation of MPPs
The sequences of theMPPswere designed to display two proper-
ties known tobe important forpassageacrossboth theplasmaand
mitochondrial membranes: positive charge and lipophilic charac-
ter.Previousstudiesofarginine-basedpeptideoligomers indicated
thathigh levelsofcellularuptakecanbeachieved through the inclu-
sion of cationic residues (Wender et al., 2000). The positivemolec-
ular charge facilitates charge-driven uptake through the plasma
membrane,which exhibits a potential gradient that will electropho-
rese cationic species from the extracellular space into the cell
(Rothbard et al., 2004; Terrone et al., 2003). Given that the mito-
chondrial membrane is a similarly energized interface, including
cationic residues in the sequences should, in principle, allow pas-
sage through both membranes. However, the inner membrane of
this organelle is much more hydrophobic than the plasma
membrane, which necessitates preservation of a high degree of
lipophilicity in order to allow partitioning of the peptides through
the lipid bilayer. The successful delivery of a peptide antioxidant
to mitochondria that contained alternating aromatic and cationic
residues indicates that this motif is an effective one for mitochon-
drial delivery (Zhaoet al., 2004). Thus, wemadeoligomers contain-
ing cationic and hydrophobic residues that would provide electro-
Figure 1. Uptake of MPPs
(A) Structures of peptides used for analysis. The
peptides consisted of four or eight amino acids
and were linked to the fluorophore, to, for imaging.
d-Arginine (r) was included in the conjugates to in-
crease cellular stability. The Tat49–57 peptide was
also synthesized, modified with to, and used as
a standard.
(B) Uptake of MPPs in human cell lines measured
by flow cytometry. HeLa, MCF-7, or MRC-5 cells
were incubated with 2.5 mM peptide for 90 min
before cytometry trials. Data shown represent
means and standard error of a minimum of three
trials. The toxicities of the MPPs were monitored
to ensure that all measurements were obtained
with viable cells (see Figure S2).
static driving force for uptake through the
energizedplasmaandmitochondrialmem-
branes,whilepreserving the lipophilicchar-
acter that would facilitate passage through
the latter. Lysine (K) and arginine (R) were
selected to provide positive charge, and
phenylalanine (F) and cyclohexylalanine
(FX) residueswereused to impart lipophilic-
ity. Peptides containing either four or eight
residues were synthesized and labeled
with the fluorophore thiazole orange (to;
Figure 1A).
Analysis of MPP Cellular Uptake
and Localization
The cellular uptake and localization of the
sequences was evaluated in human cells
by flow cytometry and confocal micros-
copy. The uptake of the designed peptides was analyzed in three
different cell lines: HeLa (a cervical carcinoma cell line), MCF-7 (a
breast carcinoma cell line), and MRC-5 (a normal lung fibroblast
cell line) (Figure 1B). The Tat peptide was also modified with the
same fluorophore and analyzed for comparison. In all the cell
lines tested, uptake of the designed MPPs approached that of
Tat, indicating that efficient transport through the plasma mem-
brane was achieved. The uptake of the sequence FXrFXKFXrFXK
(1a) in the two cancer cell lines was particularly strong, and was
comparable to that observedwith Tat. These results indicate that
success was achieved in generating sequences with favorable
uptake, and that efficient transport of these compounds into
cells is observed in a variety of cell types.
The analysis of peptide localization within HeLa cells revealed
that, while uptake across the plasma membrane of Tat and the
lipophilic peptides was similar, the intracellular localization was
profoundly different (Figure 2). The oligomers designed to func-
tion as MPPs exhibited strong mitochondrial localization, while
the Tat peptide was excluded from mitochondria and, instead,
appeared within the nuclei. By colocalizing the peptides with
Mitotracker CMXRos (Invitrogen) and comparing the images cor-
responding to the fluorescence profiles, Pearson’s correlation
coefficients (Rr) could be calculated reflecting mitochondrial
specificity. The two peptides containing FX residues displayed376 Chemistry & Biology 15, 375–382, April 2008 ª2008 Elsevier Ltd All rights reserved
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Mitochondria-Penetrating PeptidesFigure 2. Localization of MPPs in Live HeLa Cells
Cells were incubated with peptide for 90 min before imaging; 25 nM Mitotracker CMXRos was introduced 15 min before images were acquired. Peptide con-
centrations were adjusted (1–10 mM) to achieve equivalent uptake for the panel of peptide conjugates. Images shown in green correspond to those of the peptides
and those shown in red correspond to Mitotracker. Images collected for both compounds were analyzed with an algorithm for the calculation of Rr to determine
the extent of mitochondrial localization for the peptides. Values reportedwere calculated frommore than 100 cells analyzed inmultiple (>3) experiments. Only live
cells (as judged by the exclusion of PI) were included in the analysis. Scale bar, 10 mm.very high levels of mitochondrial localization (Rr = +0.5 to +0.6),
while those containing F residues were less mitochondrial (Rr =
+0.2), and Tat displayed essentially no mitochondrial localization
(Rr = 0.3). These results demonstrate that the artificial se-
quenceswe engineeredwere successfully targeted tomitochon-
dria, but the different levels of mitochondrial specificity for the
FX-containing sequences relative to those containing F indicates
that subtle changes to the chemical structure of the peptide had
a significant effect on localization.
It is noteworthy that, in the experiments shown in Figure 1B
and Figure 2, 90 min incubations were used to enhance the qual-
ity of the images obtained by confocal fluorescencemicroscopy.
However, experiments were also performed to monitor uptake
and localization of the MPPs with shorter incubation times. As
described in Figure S4 in the Supplemental Data (available with
this article online), uptake comparable to that of Tat was
obtained and similar localization profiles were observed when
shorter (e.g., 15 and 30 min) incubations were examined.
Elucidation of Molecular Requirements
for Mitochondrial Localization
To explore the nature of the relationship between chemical
structure and the cellular localization of MPPs, we synthesized
a panel of compounds with a variety of functional groups
(Figure 3 and Table 1). As we envisaged that lipophilicity would
be important in modulating the localization of the conjugates,
structures were selected that would exhibit significant variations
in this parameter. The compounds incorporated several hydro-
phobic amino acids, including unnatural residues displaying
diphenyl, naphthyl, or hexyl functionalities. Fluorinated F (FF),
methylated tyrosine (YMe), and tyrosine (Y) residues were also
utilized to enhance chemical diversity within the panels of
conjugates tested.Chemistry & BiologyThe calculation of correlation coefficients describing the
extent of mitochondrial localization for all 14 compounds in-
cluded in this study revealed that the members of the panel
exhibited a wide variety of intracellular localizations (Table 1).
For example, as shown in Figure 3B, within the set of compounds
bearing a +3 charge, some compounds displayed exclusively
mitochondrial localization, others were completely excluded
from the mitochondria, and others exhibited mixed localization,
appearing both in the mitochondria and nuclei of HeLa cells.
While it is not possible to determine unequivocally from this
analysis the exact suborganellar location of the peptides that
enter into mitochondria, it is likely that they do not remain in the
mitochondrial membrane, as the sequestration of cationic pep-
tides in this environment would be energetically unfavorable. It
is therefore reasonable to expect that they would enter the ma-
trix, but this is a difficult issue to address experimentally.
Examination of the correlation between mitochondrial locali-
zation and the lipophilicity of the +3 peptide conjugates revealed
a striking trend (Figure 4). Compounds that possessed log P
values higher than 1.7 exhibited strong mitochondrial localiza-
tion, while those with log P values lower than 2.0 were essen-
tially excluded from mitochondria, and instead appeared in the
nuclei and cytoplasm of HeLa cells. In the range between these
two values, mixed localization was observed that demonstrated
a strong dependence on lipophilicity. Thus, there appears to be
a critical lipophilicity threshold where mitochondrial entry is per-
mitted, with hydrophilicity above this level decreasing compati-
bility with the mitochondrial membrane and precluding access.
Interestingly, there is a well-defined lipophilicity threshold that
is required for mitochondrial penetration. Indeed, these cationic
compounds with a +3 charge must possess sufficient lipo-
philicity (i.e., that reflected in a log P value of approximately
2.0 or higher) to access mitochondria.15, 375–382, April 2008 ª2008 Elsevier Ltd All rights reserved 377
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Mitochondria-Penetrating PeptidesFigure 3. Evaluation of Mitochondrial Localization for Synthetic Peptide Conjugates
(A) The peptidoconjugate scaffolds tested consisted of four or eight amino acids linked to the fluorophore, to. The lysine and arginine residues shown schemat-
ically in gray were held constant (along with the fluorophore, to), and the residues in red were altered to modulate lipophilicity. The tetramer conjugates possess
a charge of +3, while the octamers possess a charge of +5.
(B) Quantitation of mitochondrial localization via calculation of Rr for +3 peptide conjugates. Coefficients were calculated as described in the Experimental
Procedures. Images for octameric peptides can be found in the Supplemental Data.When the larger compounds possessing a +5 charge were
examined, the same strong relationship between lipophilicity
and mitochondrial localization was observed (Figure 4). How-
ever, the lipophilicity threshold for mitochondrial localization
shifted relative to the +3 compounds,withmore hydrophilic com-
pounds still penetrating the organelle. Peptides with log P values
of 2.5 and higher exhibited mitochondrial localization, while
a log P value of 2.7 appeared to promote exclusion from mito-
chondria. Thus, for compounds bearing this elevated charge, the
lipophilicity threshold is decreased to approximately2.6. These
results suggest that the charge-driven uptake of these conju-
gates into mitochondria dominates the localization, and that
a greater electrochemical driving force provided by additional
charge can provide enough energy to propel a more hydrophilic
species through the hydrophobic mitochondrial membrane.
The approach described here, in which confocal fluorescence
microscopy and flow cytometry were used to extract systematic
trends describing how the chemical properties of peptides influ-
ence subcellular localization, relies on the use of an appended
fluorophore, to. While this moiety could influence the behavior
of these peptides, it is important to recognize that it is a constant
throughout all of the experiments described, which minimizes
the likelihood that the localization trends observed are related
to the fluorophore. As shown, changes to the peptide sequence
have a direct effect on the localization profiles of the compounds,
indicating that the behavior observed truly results from the vary-
ing chemical properties of differing side chains. While towas the
best choice as an imaging label for the experiments described
because of its spectroscopic properties (e.g., its high extinction
coefficient and quantum yield) and yielded high-resolution
images suitable for the quantitative approach that we pursued,378 Chemistry & Biology 15, 375–382, April 2008 ª2008 Elsevier Ltdwe also investigated the localization of peptides featuring other
fluorophores to ensure that our chromophore was not influenc-
ing the localization of the MPPs. For example, the inclusion of
2-aminobenzoic acid (abz) in MPPs allowed us to assess locali-
zation in the absence of the to chromophore. Indeed, the locali-
zation profiles of abz-modified peptides were qualitatively com-
parable to those observed with to (see Figure S5), and confirm
that the fluorophore used in the majority of our studies is not
dominating the behavior observed.
Investigation of Charge-Driven Transport through
the Plasma and Mitochondrial Membranes
To more directly establish that charge-driven uptake is respon-
sible for the transport of the MPPs across the plasma and
mitochondrial membranes, we tested agents that would alter
membrane potentials and monitored the effects on uptake and
localization. While many CPPs, including Tat, have been shown
to enter cells by endocytosis (Fotin-Mleczek et al., 2005; Gump
and Dowdy, 2007), some artificial sequences have been shown
to traverse the plasma membrane by direct potential-driven
diffusion (Henriques et al., 2005; Rothbard et al., 2004; Terrone
et al., 2003). Given the results presented above, it appeared
that this direct mechanism could dominate the uptake and
subcellular trafficking of MPPs. Indeed, while treatment with
endocytosis inhibitors did not decrease the uptake of the
MPPs (data not shown), treating with gramicidin or valinomycin
(two agents that alter the plasmamembrane potential) (Rothbard
et al., 2004; Urban et al., 1980) did have a pronounced effect on
uptake (Figure 5A). The use of gramicidin to depolarize the
plasma membrane decreased the uptake of peptide 1a by
80%. Likewise, a 110% increase in uptake for 1a was observedAll rights reserved
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membrane potential greatly enhanced transport across the lipid
bilayer. The relative uptake of the compounds across the panel
of cell lines (Figure 1B) also suggests a membrane potential-
drivenmechanismof uptake, since uptake increasedwith plasma
membrane potential of the cell lines (MRC-5 [67 ± 9 mV] < HeLa
[75 ± 7 mV] < MCF-7 [103 ± 11 mV]).
Perturbing the mitochondrial membrane potential also
influenced the behavior of the MPPs. In the presence of the
mitochondrial decoupler FCCP, the localization profile of
compound 1a was dramatically altered, and mitochondrial up-
take was significantly decreased (Figure 5B). These results,
taken together, indicate that the MPPs are successful in pene-
trating the plasma and mitochondrial membranes because
they are able to respond to the potential gradients that exist
across these interfaces. It is noteworthy that there are known
examples of mitochondrially localized agents (e.g., 10-N-nonyl
acridine orange [Petit et al., 1995]) that exhibit this type of organ-
ellar specificity due to association with cardiolipin. The potential
dependence we observe here indicates that it is an electrochem-
ical gradient, rather than a specific type of complexation, that is
responsible for the mitochondrial localization of a subset of the
peptide sequences described. However, from these experi-
ments, we cannot rule out that cardiolipin might play a role.
Comparison of MPPs to Other Mitochondrially
Localized Molecules
Prior work on the development of mitochondrial transporters has
primarily focused on the use of lipophilic delocalized cations that
Table 1. Lipophilicity and Mitochondrial Localization of Peptide
Conjugates
Compound Charge Log Pa Rrb
to-FX-r-FX-K-FX-r-FX-K (1a)
c +5 2.2 +0.5
to-F-r-F-K-F-r-F-K (1b) +5 2.5 +0.1
to-F-r-FX-K-F-r-FX-K (1c) +5 2.3 +0.4
to-F-r-Y-K-F-r-Y-K (1d) +5 2.7 0.4
to-FX-r-FX-K (2a) +3 1.1 +0.6
to-F-r-F-K (2b) +3 1.9 +0.2
to-F-r-FX-K (2c) +3 1.4 +0.4
to-F-r-F2-K (2d) +3 1.6 +0.6
to-F-r-Nap-K (2e) +3 1.6 +0.5
to-F-r-Hex-K (2f) +3 1.7 +0.5
to-F-r-YMe-K (2g) +3 2.0 +0.1
to-F-r-FF-K (2h) +3 2.0 0.1
to-F-r-Y-K (2i) +3 2.1 0.2
to-Y-r-Y-K (2j) +3 2.4 0.4
Abbreviations: F, phenylalanine; F2, diphenyl; FX, cyclohexylalanine; Hex,
hexyl; K, l-lysine; Nap, naphthyl; r, d-arginine; Rr, Pearson’s correlation
coefficient; to, thiazole orange; Y, tyrosine; YMe, methylated tyrosine.
a Log P values measured by the shake-flask method. See Figure 4 for
standard errors of values.
bRr values measured by confocal microscopy and comparison of
Mitotracker with fluorescence from labeled conjugate. See Figure 4 for
standard errors.
c The residue r was included to increase protease stability of conjugates.
See the Supplemental Data for chemical structures of compounds and
characterization.Chemistry & Biologyharness the mitochondrial membrane potential to enter the
organelle (Murphy and Smith, 2000; Horobin et al., 2007;
Modica-Napolitano and Aprille, 2001; Davis et al., 1985). This
approach has been successful when applied to deliver nonpolar
species into mitochondria, but has not been successful when
more polar cargos are targeted. Indeed, the conjugation of a li-
pophilic cation to a CPP did not facilitate its uptake into mito-
chondria, and this observation was taken as evidence that pep-
tides would not permeate the inner mitochondrial membrane
(Ross et al., 2004). We show here that lipophilic cationic pep-
tides, while not possessing delocalized charge, can be engi-
neered to enter mitochondria. Indeed, it is noteworthy that, while
our work to our knowledge constitutes the first example of a sys-
tematic series of MPPs with efficient cellular uptake and highly
specific organellar localization, a prior report of peptide antioxi-
dants also indicated that small peptides could display this type
of organellar specificity (Zhao et al., 2004). These compounds
exhibit structural similarity to a subset of our tetrameric pep-
tides. Clearly, this previous work, and that reported here, indi-
cates that peptides are indeed a useful tool for mitochondrial
delivery.
SIGNIFICANCE
We have engineered a class of cell-permeable peptides that
efficiently enter human cells, and specifically localize to mi-
tochondria. The studies reported are, to our knowledge, the
first to systematically identify critical levels of lipophilicity
Figure 4. Correlation between Mitochondrial Localization and
Lipophilicity
Rr values are plotted against experimentally determined log P values. Com-
pounds bearing a +3 charge are plotted in red, and those with a +5 charge
are plotted in blue. Solid gray lines represent limits for Rr values obtained
when two mitochondrial dyes were colocalized (mt:mt) versus when one mito-
chondrial dye and one nuclear dye were colocalized (DAPI:mt). These control
experiments indicate that the maximum positive correlation coefficient that
can be obtained with the protocols employed is +0.7, and that the minimum
negative correlation coefficient is 0.6. The gray-shaded area on the plot rep-
resents the values of Rr reflecting mitochondrial localization. Please note that
the lines drawn through the experimental points do not represent a mathemat-
ical fit, but are instead intended to highlight the trends qualitatively. Error bars
on data points represent standard error for log P and Rr determinations.15, 375–382, April 2008 ª2008 Elsevier Ltd All rights reserved 379
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Mitochondria-Penetrating PeptidesFigure 5. Effects of Membrane Potential on
Uptake and Localization of MPPs
(A) Uptake dependence of MPPs and Tat on
plasma membrane potential. HeLa cells were
treated with valinomycin (increased membrane
potential) or gramicidin (decreased membrane
potential) before and during incubation with pep-
tide conjugates. Uptake was measured by flow
cytometry and is expressed as percent change
relative to untreated cell uptake. Data represent
themean and standard error of aminimumof three
trials.
(B) Decreasedmitochondrial localization observed
for to-FX-r-FX-K-FX-r-FX-K in the presence of
FCCP. Images were acquired under the same
conditions as described in Figure 1B.that allow molecules to access mitochondria and to eluci-
date the effect of molecular charge on lipophilicity thresh-
olds. The trends observed with these conjugates provide
insight into theexact requirements that impartmitochondrial
localization to lipophilic cations, andmayprovide ameans to
engineer the cellular trafficking of bioactive compounds.
These mitochondria-penetrating peptides (MPPs), based on
a peptide scaffold, possess characteristics conducive to use
as a delivery vector: straightforward synthesis, facile derivi-
tization, andbiocompatibility. Thus, theMPPsdescribedmay
represent a classof effectivemitochondrial transporters that
are well suited to traverse an organellar membrane that is
difficult to penetrate.
EXPERIMENTAL PROCEDURES
Preparation of MPPs
Peptides were prepared as described previously (Carreon et al., 2007). See the
Supplemental Data for protocols and characterization information.
Cell Culture
HeLa and MRC-5 cells (ATCC) were cultured as subconfluent monolayers on
25 cm2 or 75 cm2 cell culture plates with vent caps (Sarstedt) in minimum
essential medium (MEM; ATCC) supplemented with 10% (v/v) fetal bovine
serum (FBS; ATCC) in a humidified incubator (70%–95%) at 37C with 5%
CO2. MCF-7 cells were cultured in similar conditions, expect that the MEM
media were supplemented with 10% FBS and 0.01 mg/ml insulin. Cells grown
to subconfluence were enzymatically dissociated from the surface with a
solution of 0.05% trypsin/0.53mM EDTA (Cellgro) and plated at 15–25 3 103
cells/well 1–2 days prior to the experiment in eight well ibiTreat m-slides
(Ibidi). For uptake experiments, 13 105 cells/well were plated in a 12-well plate
1 day prior to the experiment. These conditions produced a monolayer at
subconfluence.
Confocal Fluorescence Microscopy
For colocalization studies, the culture medium was removed, and the cells
were washed in phosphate-buffered saline (PBS; Cellgro), pH 7.4. The cells
were incubated with 5 mM conjugate in serum-free MEM (a-MEM [no phenol
red]; Invitrogen) for 90 min. The viability of cells in the absence of serum was
investigated by microscopy and by monitoring the exclusion of the viability
dye Propidium Iodide; no losses of viability were observed, as shown in
Figure S6. Peptide concentrations were adjusted (1–10 mM) to achieve equiv-
alent uptake for the panel of peptide conjugates. Mitotracker CMXRos was
added to achieve a final concentration of 25–50 nM for the last 15 min of
the incubation. Cells were washed three times with serum-free MEM. After
washing, serum-free MEM was added and the slides were placed on ice.
Images were taken with an inverted Zeiss LSM 510 confocal microscope
with a water immersion lens (633). The excitation wavelength for visualization380 Chemistry & Biology 15, 375–382, April 2008 ª2008 Elsevier Ltdof to conjugates was 488 nm, and emission was collected from 505 to 550 nm.
The excitation wavelength for visualization of Mitotracker CMXRos was
543 nm, and emission was collected with a long-pass 560 nm filter. Differential
interference contrast (DIC) images were taken along with both fluorescence
channels, and no bleedthrough was observed during colocalization studies
with these parameters. The fluorescence images were analyzed with the
Colocalizer Pro software program to determine Rr, and values reported are
average values obtained for individual representative cells (100 cells) over
multiple experiments (R3 days). The background was subtracted from the im-
ages with amanually selected region of interest. Mitotic and unhealthy cells, as
assessed by DIC, were excluded from analysis. Because large differences in
signal intensity between the two fluorescence channels can introduce
artifacts, only cells with comparable signals from both channels were used
for calculations.
To assess localization in cells with altered mitochondrial membrane
potential, the proton ionophore carbonylcyanide p-trifluoromethoxy phenyl-
hydrazone (FCCP) was used to decrease mitochondrial membrane potential.
Cells were pretreated with 10 mM FCCP in serum-free MEM for 15 min at in
a humidified incubator at 37C with 5% CO2. This solution was removed and
the cells were incubated with 2 mM to-FX-r-FX-K-FX-r-FX-K in serum-free
MEM in the presence of 10 mM FCCP for 30 min. After incubation, the
solution was removed and the cells were washed with MEM and placed
on ice until imaging.
Flow Cytometry
After incubation with 5 uM peptide for 90 min, cells were enzymatically
removed from the surface of the plate with trypsin/EDTA (250 ml/well) for
10 min at 37C. The trypsinization was quenched with 500 ml complete MEM
per well, and an additional 1 ml PBS was added to each well. From this point
on, the samples were maintained on ice or at 4C until analysis. The samples
were transferred from the wells to sterile tubes, pelleted by centrifugation
(8 min at 2100 3 g), and resuspended in 500 ml PBS containing 1 mg/ml propi-
dium iodide (PI; Sigma). Samples were then analyzed by flow cytometry on
a BD FACSCanto flow cytometer (BD Biosciences). A minimum of 10,000 cells
were analyzed per sample. Those staining positive for PI were excluded
from analysis. The fluorescence median of the live population was used for
statistical analysis.
In order to test the role of membrane potential on cellular uptake, the above
procedure was repeated with solutions of 50 nM valinomycin (Sigma) or 1 mM
gramicidin (Sigma) in serum-free MEM for pretreatment and coincubation. The
cells were removed from the surface and analyzed in the same fashion. Those
staining positive for PI were excluded from analysis. Treated and untreated
cells were >80% viable.
Measurement of Log P
Log P values were measured via octanol partitioning by a modification of the
shake-flask method and as previously described (Rothbard et al., 2004). An
aliquot of 100 ml of 300 mM to-peptide conjugate in Tris buffer (10 mM, pH
7.4) and 100 ml 1-octanol (Aldrich) were added to a 0.5 ml microtube. Buffer
was employed in order to measure log P of the peptide conjugates in theAll rights reserved
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1 min and centrifuged; 25 ml of each layer was removed and diluted in 100
ml 3:1 methanol:Tris or methanol:octanol for a final composition of 3:1:1
methanol:octanol:Tris. The aqueous layer was diluted an additional 4-fold.
Three dilutions were prepared per layer, 100 ml of each dilution was pipetted
into a 384 well plate, and the absorbance read at 500 nm with a reference
wavelength at 625 nm. The mean A500 of three dilutions was calculated for
each layer. The log (A500 of the organic layer/A500 of the aqueous layer)
yielded log P. For compounds with very low lipophilicity (log P < 2.3),
the volume of the octanol and aqueous layers was increased from 100 to
125 ml, and the absorbance of the octanol layer was measured without
any additional dilutions. This procedure was repeated a minimum of three
times per conjugate to calculate the mean log P and standard error.
All absorbance measurements used were within the linear range of the
instrument.
SUPPLEMENTAL DATA
Supplemental Data include synthetic protocols and compound characteriza-
tion information, and procedures used to measure membrane potentials,
and are available with this article online at http://www.chembiol.com/cgi/
content/full/15/4/375/DC1/.
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